Literature DB >> 404555

Evaluation of tetracycline or penicillin and ampicillin for treatment of acute pelvic inflammatory disease.

F G Cunningham, J C Hauth, J D Strong, W N Herbert, L C Gilstrap, R H Wilson, S S Kappus.   

Abstract

To evaluate guidelines for outpatient treatment of acute pelvic inflammatory disease recommended by the Center for Disease Control we studied 197 afflicted women. The women were treated either with tetracycline or with procaine penicillin and ampicillin, and 92% were subsequently seen at least once to assess efficacy of clinical and microbiologic treatment. Neisseria gonorrhoeae was isolated from the lower genital tract in 68% of these women, and although they had a quicker symptomatic response than those with nongonococcal infection (P less than 0.01), the two regimens were equally effective in producing clinical cure. However, subsequent identification of a pelvic abscess was 10 times more common in women from whom N. gonorrhoeae was not isolated. Therapy for pelvic inflammatory disease must be empirical since it is impossible to distinguish clinically between gonococcal and nongonococcal infection, and our data indicate that both regimens recommended by the Center for Disease Control are effective.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 404555     DOI: 10.1056/NEJM197706162962404

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  3 in total

1.  Tetracyclines in gynecologic infections.

Authors:  W J Ledger
Journal:  Bull N Y Acad Med       Date:  1978-02

Review 2.  Pelvic inflammatory disease: current concepts and treatment guidelines.

Authors:  P A Dale; P A Rice; K C Edelin
Journal:  J Gen Intern Med       Date:  1986 Nov-Dec       Impact factor: 5.128

Review 3.  Gonococcal Pelvic Inflammatory Disease: Placing Mechanistic Insights Into the Context of Clinical and Epidemiological Observations.

Authors:  Stacey X Xu; Scott D Gray-Owen
Journal:  J Infect Dis       Date:  2021-08-16       Impact factor: 7.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.